RELEASE: Philips partners with SyntheticMR to improve neurological care for patients

(Information sent by the signatory company)

"Innovative Smart Quant Neuro 3D technology enables 3D multi-enhancement results using a single MRI sequence and automatic measurement of various brain tissues to improve brain disease decision-making, assess progression and monitor the effect of the therapy"

Analysis of volumetric myelin quantification maps provides an objective evaluation of traumatic brain injuries that were previously only diagnosed based on the patient's clinical symptoms.

Royal Philips, a global leader in healthcare technology, and magnetic resonance imaging (MRI) software solutions company SyntheticMR (based in Linköping, Sweden) have announced the launch of Smart Quant Neuro 3D, a major advance in supporting objective decision making for the diagnosis and therapeutic evaluation of brain disorders such as multiple sclerosis (MS), traumatic brain injury (TBI), and dementia.

Smart Quant Neuro 3D combines Philips' AI-based SmartSpeed ​​image reconstruction technology, Philips 3D SyntAc clinical application, and SyntheticMR's SyMRI NEURO 3D quantitative tissue assessment software. The combined offering provides healthcare professionals with powerful tools for greater diagnostic confidence, ultimately benefiting patients. Philips' exclusive agreement with SyntheticMR makes it the only company that can currently offer SyMRI NEURO 3D functionality in MR scanners.

Accurate measurement of the volume and distribution of different types of tissue in the brain is important for diagnosing brain diseases. However, visual assessments of MR images are often subjective and lack the necessary precision, while measurement of tissue volume from 2D image slices is virtually impossible. Smart Quant Neuro 3D harnesses the power of AI to provide fully verified, automatic, accurate 3D segmentation and volume measurement of brain tissue such as white matter, gray matter, cerebrospinal fluid, and myelin. When interpreted by a specialist, these measurements can provide useful information in determining the diagnosis of patients.

"Brain injuries and neurodegenerative diseases are two of the most difficult diagnoses that clinicians have to make on a daily basis, due to the impact they can have on the patient's subsequent quality of life and the variability in the symptoms that each patient presents," said Ruud Zwerink, RM Business Leader at Philips.

With Smart Quant Neuro 3D, clinicians have access to an easy-to-use tool that provides valuable quantitative data to track the impact of treatments and make informed decisions about adjustments or alternative interventions as needed. This continuous monitoring improves patient care by enabling proactive management of neurological conditions and optimizing therapeutic outcomes for patients.

"Smart Quant allows for shorter exams and exploration of quantitative metrics, which shows great potential to better stratify patients with similar imaging characteristics in conventional MR sequences. It is a rapid quantitative MR technique that is integrated into our flow of clinical work and allows us to generate multiple weighted images synthetically from a single sequence," says Dr. Julien Savatovsky, Neuroradiologist and head of the Radiology Service at the Adolphe de Rothschild Hospital Foundation in Paris.

Greater confidence in the diagnosis

Smart Quant Neuro 3D is especially effective in measuring myelin, the insulating layer that surrounds nerves and ensures that electrical impulses from the brain reach their destination. Myelin loss is one of the main characteristics of traumatic brain injuries, so Smart Quant Neuro 3D's ability to detect abnormalities that are currently invisible on conventional MRI scans helps with early diagnosis and intervention. .

By quantitatively measuring myelin, doctors can better understand the extent and impact of TBI and differentiate it from other neurological diseases.

The ability to quantify the degree of myelin loss or damage in a patient's brain is also important in progressive brain diseases such as multiple sclerosis. Quantitative measurement of myelin loss allows doctors to evaluate the disease, follow its progression over time, and evaluate the effect of the latest drugs intended to treat the disease. The additional information provided by Smart Quant Neuro 3D benefits patients as all relevant clinical MR contrasts are available from a single acquisition, avoiding the need to call patients back for additional data.

Improved workflow efficiency

Using Philips AI-based SmartSpeed ​​MR reconstruction technology, which triples the imaging speed and provides up to 65% more resolution, Smart Quant Neuro 3D makes it easier to scan patients and can help speed up performance of the radiology department. SyntheticMR's SyMRI NEURO 3D software then performs automatic (no-click) analysis of the image data to provide accurate segmentation and tissue volume measurement in less than 10 seconds of post-processing.

A whole world of care

Philips innovations are underpinned by the company's commitment to driving sustainable healthcare, developing solutions that help care for patients and the planet with the same care and dedication. "Investing in sustainability in all our operations and working closely with our clients and the industry, offering our sustainable innovations and digital solutions, are our hallmarks to help build the future of health," says Miguel de Foronda, general director. from Philips Ibérica.

Philips' global campaign "Care means the world" is an example of how Philips seeks a transition towards a more sustainable health system, caring for our planet with the same attention and urgency with which we care of our patients.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHI) is a leading health technology company, focused on improving people's health and well-being, and facilitating better results in the health cycle, from habits healthy and prevention, to diagnosis, treatment and home care. Philips leverages its advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as consumer health and home care. Philips has recorded sales of €18.2 billion in 2023 and employs approximately 69,700 employees, with business operations and services in more than 100 countries. All news about Philips can be found in our News Center.

Issuer: Royal Philips

Contact: César García Requena, Brand